TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06646016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen
Description: Sterile solution used in conjunction with photopheresis procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab will be administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab
Description: Vedolizumab will be administered intravenously.
Study: NCT06151574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zongertinib
Description: zongertinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: pembrolizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: platinum-pemetrexed chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: platinum-pemetrexed chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: platinum-pemetrexed chemotherapy
Study: NCT06647524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC
Description: Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Participants will be administered 0.5g of vaporized THC cannabis (12% THC cannabis)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered identical plant material from which all THC has been removed by solvent extraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered identical plant material from which all THC has been removed by solvent extraction.
Study: NCT06386094

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic assessment
Description: M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
Study: NCT06646432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel with connective tissue graft and injectable platelet rich fibrin
Description: Tunnel with connective tissue graft and injectable platelet rich fibrin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnel with connective tissue graft only
Description: Tunnel technique with connective tossue graft only without injectable platelet rich fibrin
Study: NCT06634355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured.
Study: NCT05220319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 250 mg Methylprednisolone made up with 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional dose in 100 ml will be given.
Study: NCT04937062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
Description: Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
Description: Glycerol phenylbutyrate (trade name Ravicti) is an FDA-approved medication used for urea cycle disorders in children and adults. We will titrate to a goal dose of 1.2 mL/m2 (12.4 g/m2) in three equally divided doses given enterally (i.e., by mouth or by g-tube).~The dosing is consistent with the dosing guidelines in the FDA approved Medication Guide (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf).
Study: NCT04098250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: a CGRP receptor monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05767034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to secukinumab
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
Study: NCT06348329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth Preparation Training
Description: Birth Preparation Training is planned to include a 4-week program by an internationally certified instructor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth Preparation Training
Description: Birth Preparation Training is planned to include a 4-week program by an internationally certified instructor.
Study: NCT05287594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Exercise Program
Description: Neuromuscular warm-up: Each participant will perform a series of dynamic stretches, core stability, balance, and medicine ball exercises. The dynamic stretches include 8 repetitions of 6 stretches targeting the hip and thigh musculature, followed by 3 core stability isometric exercises (curl-up, side bridge, and bird dog). Participants will then perform 2 sets (per leg) of hop-to-stabilization (with a reach) balance exercises, followed by 3 separate medicine ball exercises emphasizing explosive full-body movements.~High Intensity Interval Training (HIIT): HIIT will include a series of high intensity exercise bouts on a stationary bike that includes a 1:1 work-to-rest ratio. Training intensity will be determined from the peak power output obtained during the baseline VO2 peak assessment and progressively increased by the number of bouts and intensity. The number of work bouts will increase from 5 to 8 bouts and the intensity will increase from 90 to 110% of peak power output.
Study: NCT05450601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2102-1
Description: Take once daily for 2 weeks orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2104-1
Description: Placebo drug. Take once daily for 2 weeks orally
Study: NCT06232564

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
Description: Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
Study: NCT06423820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron lozenge
Description: Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
Study: NCT05744687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336 Tablets 400mg
Description: SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPH4336 Tablets Placebo
Description: SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle
Study: NCT06346392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab+ paclitaxel
Description: Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)
Study: NCT06018064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Positioner
Description: An innovative device to allow for infants to be supported while in the prone position
Study: NCT05621291

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NGS testing
Description: antigen immunophenotype agnostic approach for disease detection using blood and bone marrow samples
Study: NCT06348316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half swaddle
Description: Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half swaddle
Description: Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
Study: NCT05712694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
Study: NCT05450601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2102-2
Description: Take once daily for 6 weeks orally
Study: NCT05220319

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
Study: NCT06556095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg/ml solution
Description: The study intervention dexamethasone solution (4mg/ml) is used to hydrate bone allograft.
Study: NCT05305118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSCS Mapping
Description: Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device).
Study: NCT05289817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (t-VNS)
Description: Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)
Description: Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)
Description: Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes
Study: NCT06398730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection and GEH200521 (18F) Injection
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection and GEH200521 (18F) Injection
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection and GEH200521 (18F) Injection
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection and GEH200521 (18F) Injection
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection and GEH200521 (18F) Injection
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection and GEH200521 (18F) Injection
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection and GEH200521 (18F) Injection
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
Study: NCT05712694

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
Study: NCT06442787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional splints
Description: only intermediate and final splint will be used during the surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cutting guides and positioning guides
Description: patient's specific manufacturing cutting guide and positioning guide related with orthognathic surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cutting guides and fixation plates
Description: patient's specific manufacturing cutting guide and fixation plates related with orthognathic surgery
Study: NCT05836870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Participants will receive general recommendations to maintain physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-supervised resistance exercises
Description: Participants will take part in a monitored exercise program.
Study: NCT06398730

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
Study: NCT06063395

Intervention type: PROCEDURE
Intervention: open surgery on the abdominal aorta by laparotomy
Description: Laparotomy aortic surgery for the management of an abdominal aortic aneurysm has several distinct stages which will not be altered by the performance of this study. The patient arrives in the operating room and is taken care of by the anesthetic team. The patient is then placed in the correct position for optimal surgical management and a skin cleansing procedure is carried out. A sterile drape is applied and the preoperative checklist in force in the establishment is completed. Initial dissection of the aneurysm and its proximal and distal control is left to the discretion of the principal surgeon. Once the aortic aneurysm has been controlled, the main surgeon places self-static retractors and then prepares to clamp the aorta. The surgeon initiates aortic clamping to create the aorto-biliac or bifemoral bypass. Once the bypass has been created, the operation is completed by closing the surgical approach and the skin incision. The bandage is then applied.
Study: NCT06072781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib
Description: Avutometinib: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib: administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: administered orally